Effective Clinical Practice
Trends in the Use of Radical Prostatectomy for Treatment of Prostate Cancer
Effective Clinical Practice, September/October 1999.
Lars M. Ellison, John A. Heaney, John D. Birkmeyer
For author affiliations, current addresses, and contributions, see end of text.
Context. The incidence of prostate cancer and rates of radical prostatectomy increased sharply in the Medicare population (men older than 65 years of age) after the introduction of prostate-specific antigen screening in the late 1980s.
Practice Pattern Examined. Trends in age-specific rates of use of radical prostatectomy in U.S. men between 1989 and 1995.
Data Source. The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program.
Results. Overall, rates of radical prostatectomy more than doubled between 1989 and 1992 (from 78 per 100,000 men to 206 per 100,000 men) but decreased by a third between 1992 and 1995 (to 146 per 100,000 men). The pattern in overall radical prostatectomy rates between 1992 and 1995, however, obscures changes that occurred for men in different age groups. Decreases in radical prostatectomy rates were most dramatic in elderly persons, dropping 51% in men 70 to 74 years of age and 71% in men 75 years of age or older. In contrast, rates in younger men continued to increase between 1992 and 1995, rising 42% in men 45 to 49 years of age and 18% in men 50 to 54 years of age. In each age group, trends in surgery rates mirrored trends in cancer detection rates.
Conclusions. Surgical treatment of prostate cancer in older men is decreasing; however, surgery rates are increasing in younger men. These divergent trends reflect the pattern of prostate cancer detection in clinical practice.
Prostate-specific antigen (PSA) testing, which came into wide clinical use in 1987, uncovered a large reservoir of asymptomatic men who had prostate cancer that was undetectable by digital rectal examination. The overall incidence of prostate cancer increased 82% between 1986 and 1991. (1, 2) More cases were detected at earlier stages and thus were amenable to surgical resection by radical prostatectomy. (3) As a result, use of this procedure increased dramatically. For example, rates of radical prostatectomy in Medicare beneficiaries increased more than fourfold between 1987 and 1992. (4, 5)
In the early 1990s, however, questions about the value of early detection and aggressive treatment of prostate cancer, particularly in elderly men, began to appear in the medical literature. (6-16) Rates of prostate cancer detection and rates of radical prostatectomy began to decrease concomitantly in the Medicare population. (17) To examine trends in all age groups, we studied men undergoing radical prostatectomy between 1989 and 1995 by using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program.
Rates of prostate cancer incidence and radical prostatectomy were obtained from the SEER public-use database. (18) The SEER program is the federal government's primary effort to collect data about and report on cancer incidence, initial treatment, and survival (subsequent treatment and recurrence data are not collected). Trained abstractors collect information from hospital records, outpatient clinics, radiation centers, private laboratories, and physicians' offices. The SEER database includes information from population-based cancer registries in various areas of the country, including Connecticut, Iowa, New Mexico, Utah, Hawaii, and the metropolitan areas of Detroit, San Francisco, Seattle-Puget Sound, and Atlanta. These areas include approximately 10% of the U.S. population.
The primary goal of our analysis was to describe trends in rates of radical prostatectomy in different age groups, not to test specific hypotheses. Because of the large sample sizes, population-based rates generated from the SEER database are very precise. For example, the 95% CI for the 1992 rate of radical prostatectomy in men 75 years of age or older (the smallest age group examined in our analysis and therefore the one yeilding the least precise rates) was 84 ąSD 8 per 100,000 men. For simplicity, we display age-specific rates standardized to 1989 (i.e., the rate for each age group starts at 1 in 1989). Standardized rates are interpreted as follows: If the standardized rate is 2, rates have doubled; if the standardized rate is 0.5, rates have halved. Absolute rates for men in different age groups by year are given in the Appendix.
Our secondary goal was to compare rates of surgery with those of prostate cancer incidence. We used only incidence for treatable disease. Ideally, we would have used the tumor, node, metastasis (TNM) staging system, as defined by the American Joint Committee for Cancer Staging and End Results Reporting. However, because of the structure of SEER reporting before 1995, we were limited to using a more generic staging system. We excluded patients who had metastatic disease at the time of initial diagnosis (approximately 27% of incident prostate cancer cases in 1989 and 17% of incident prostate cancer cases in 1995) because these patients would not have been considered for radical prostatectomy. We combined patients identified as having localized or regional disease and considered them to be treatable.
Overall, rates of radical prostatectomy increased sharply (160%) between 1989 and 1992 but decreased 29% between 1992 and 1995. The change in overall rates, however, obscures distinct trends for men in different age groups. Figure 1 shows the extent to which recent trends in radical prostatectomy are, in fact, age-dependent.
The recent decline in overall rates is solely attributable to the decreasing use of radical prostatectomy in men older than 60 years of age. The largest relative decline in surgery rates (71%) between 1992 and 1995 occurred in men 75 years of age and older. In absolute terms, the largest decline occurred in men 70 to 74 years of age (from 449 per 100,000 men to 220 per 100,000 men).
In younger men, however, rates of radical prostatectomy increased throughout the study period. Surgery rates in men younger than 60 years of age increased dramatically between 1989 and 1992 and continued to rise at a slower rate after 1992. Between 1992 and 1995, surgery rates rose 42% in men 45 to 49 years of age and 17% in men 50 to 54 years of age.
The divergent trends in surgery rates in men of different ages could be caused by changes in the rates of detection or changes in treatment strategy. As shown in Figure 2, detection of nonmetastatic prostate cancer increased dramatically between 1989 and 1992. Although detection continued to rise after 1992 for men younger than 60 years of age, rates fell to levels near those of 1989 for men older than 70 years of age. For all age groups, trends in rates of radical prostatectomy were very similar to the reported incidence of prostate cancer (as evidenced by the similar patterns in Figures 1 and 2).
In contrast, Figure 3 shows that patterns of treatment for cases of prostate cancer (once detected) were relatively stable during the study period. As expected, the proportion of men with nonmetastatic prostate cancer who were undergoing surgery varied according to age. Men younger than 60 years of age were most likely to undergo radical prostatectomy; men older than 70 years of age were most likely to receive radiation therapy (external beam or brachytherapy) or other treatments (including hormonal treatment or watchful waiting). For all age groups, a slightly higher proportion of patients with prostate cancer underwent radical prostatectomy in 1992 than in 1995. However, these differences were small when compared with much larger changes in absolute surgical rates.
As is reflected by national trends in radical prostatectomy rates, the management of prostate cancer has changed substantially over the past decade. Soon after introduction of PSA screening in the late 1980s and dramatic increases in prostate cancer detection rates, surgery rates rose sharply in men of all age groups. After 1992, however, rates of radical prostatectomy continued to increase (albeit at a lower rate) in men younger than 60 years of age but decreased substantially in older men. In each age group, changes in surgery rates over time seemed to reflect changes in clinical decision making about diagnosis, not treatment; trends in radical prostatectomy rates closely mirrored those in prostate cancer. However, the proportion of men in different age groups who received a diagnosis of nonmetastatic prostate cancer and had radical prostatectomy did not change substantially over time.
Incidence of prostate cancer in older men may be decreasing for two reasons. First, it has been suggested that widespread use of PSA testing in the late 1980s and early 1990s may have exhausted a preexisting reservoir of prevalent cases of early-stage prostate cancer. (19) Therefore, more recent rates reflect a steadier state of incident cases. Alternately, physicians may not be screening as vigorously for prostate cancer with PSA tests, digital rectal examinations, and prostate biopsies because of increased uncertainty about the value of early detection in older men. In the absence of data from randomized clinical trials, outcome researchers have questioned the benefits that are likely to be achieved by radical prostatectomy in older men with early-stage prostate cancer. (6, 7, 20) For example, on the basis of decision analysis, Flemming and colleagues (7) estimated that radical prostatectomy increased quality-adjusted life-years by no more than 0.3 in men older than 70 years of age and that surgery may be harmful under many conditions. Enthusiasm for radical prostatectomy in older men has also been tempered by increased recognition of early and late complications. (21-24) Although more favorable results have been reported from selected referral centers, (25-29) a widely cited population-based study of 757 Medicare patients reported an approximately 40% risk for incontinence and a 90% rate of impotence after radical prostatectomy. (21) In addition, clinical authorities recommend caution in offering radical prostatectomy to older men. (30, 31) Many physicians, however, continue to screen for prostate cancer well into the eighth decade of life. (32-38)
In contrast to trends toward more conservative management of prostate cancer in elderly persons, both cancer incidence and surgery rates continue to increase in men younger than 60 years of age. In the early 1990s, the American Urological Association and the American Cancer Society instituted policy and public education initiatives encouraging PSA screening for all men after 50 years of age. (39, 40) Subsequently, screening has been widely promoted in the lay media. Enthusiasm for screening younger men may reflect the perception that radical prostatectomy has the most benefit in this group. Because of longer life expectancies, younger men may be more likely to develop symptoms or die of slowly progressing prostate cancer. In addition, younger men are, on average, more likely to have higher-grade, less-differentiated prostate cancer, which is known to be associated with a poorer prognosis when left untreated. (41, 42) Finally, younger men may have fewer complications with radical prostatectomy. (24)
Our study has several limitations. First, the SEER cancer registries do not contain information about the use of PSA or other diagnostic tests. Therefore, we cannot directly assess our hypothesis that changes in incidence of prostate cancer over time are attributable to changes in diagnostic intensity. Second, although the SEER program is widely considered the gold standard for examining cancer epidemiology in the United States, SEER rates may not perfectly reflect national patterns. The incidence of prostate cancer and rates of radical prostatectomy vary widely (up to 10-fold) across geographic regions. (4) It is possible that SEER does not contain a perfect balance of high-rate and low-rate areas.
Although we have shown that rates of radical prostatectomy are changing over time and differ by age group, our findings do not address the fundamental question, "Which rate is right?" A better understanding of the clinical risks and benefits of radical prostatectomy in different age groups awaits the results of randomized clinical trials, which are under way in the United States and Europe. In the meantime, it is important that patients understand the current uncertainties about optimal diagnosis of and treatment strategies for prostate cancer and that they participate in the decision-making process.
|Take Home Points
1. Jacobsen SJ, Katusic SK, Bergstralh EJ, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA. 1995;274:1445-9.
2. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548-52.
3. Mettlin C, Murphy GP, Lee F, et al. Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society- National Prostate Cancer Detection Project. Cancer. 1993;72:1701-8.
4. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA. 1993;269:2633-6.
5. Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst. 1996;88:166-73.
6. Cowen ME, Chartrand M, Weitzel WF. A Markov model of the natural history of prostate cancer. J Clin Epidemiol. 1994;47:3-21.
7. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA. 1993;269:2650-8.
8. Graversen PH, Nielsen KT, Gasser TC, Corle DK, Madsen PO. Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up. Urology. 1990;36:493-8.
9. Smith JA Jr, Cho YH. Management of stage A prostate cancer. Urol Clin North Am. 1990;17:769-77.
10. Jones GW. Prospective, conservative management of localized prostate cancer. Cancer. 1992;70:307-10.
11. Thompson IM, Chodak GW. The natural history of adenocarcinoma of the prostate. J Cell Biochem Suppl. 1992;16H:20-5.
12. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA. 1992;267:2191-6.
13. Johansson JE. Expectant management of early stage prostatic cancer: Swedish experience. J Urol. 1994;152(5 Pt 2):1753-6.
14. Wasson J, Fleming C, Bruskewitz R, et al. The treatment of localized prostate cancer: what are we doing, what do we know, and what should we be doing? The Prostate Patient Outcome Research Team. Semin Urol. 1993;11:23-6.
15. Adolfsson J, Steineck G, Whitmore WF Jr. Recent results of management of palpable clinically localized prostate cancer. Cancer. 1993;72:310-22.
16. Lu-Yao GL, Greenberg ER. Changes in prostate cancer inci dence and treatment in USA. Lancet. 1994;343:251-4.
17. Lu-Yao GL, Friedman M, Yao SL. Use of radical prostatectomy among Medicare beneficiaries before and after the introduction of prostate specific antigen testing. J Urol. 1997; 157:2219-22.
18. Surveillance, Epidemiology, and End Results (SEER) Program Public Use CD-ROM (1973-1995). Bethesda, MD: National Cancer Institute; 1998.
19. Stephenson RA, Smart CR, Mineau GP, James BC, Janerich DT, Dibble RL. The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence--data from the Utah Cancer Registry. Cancer. 1996;77:1342-8.
20. Beck JR, Scardino PT. How useful are models of natural history in clinical decision making and clinical research? [Editorial] J Clin Epidemiol. 1994;47:1-2.
21. Fowler FJ Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology. 1993;42: 622-9.
22. Jonler M, Messing EM, Rhodes PR, Bruskewitz RC. Sequelae of radical prostatectomy. Br J Urol. 1994;74:352-8.
23. Talcott JA, Rieker P, Propert KJ, et al. Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst. 1997;89:1117-23.
24. Talcott JA, Rieker P, Clark JA, et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol. 1998;16:275-83.
25. Catalona WJ, Bigg SW. Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J Urol. 1990;143:538-43; discussion 544.
26. Catalona WJ, Basler JW. Return of erections and urinary continence following nerve sparing radical retropubic prostatectomy. J Urol. 1993;150:905-7.
27. Drago JR, Badalament RA, York JP, et al. Radical prostatectomy: OSU and affiliated hospitals' experience 1985-1989. Urology. 1992;39:44-7.
28. Richie JP. Localized prostate cancer: overview of surgical management. Urology. 1997;49(3A Suppl):35-7.
29. Walsh PC, Lepor H. The role of radical prostatectomy in the management of prostatic cancer. Cancer. 1987;60(3 Suppl):526-37.
30. Brendler CB, Walsh PC. The role of radical prostatectomy in the treatment of prostate cancer. Ca Cancer J Clin. 1992;42:212-22.
31. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol. 1994;152(5 Pt 2):1831-6.
32. Lawson DA, Simoes EJ, Sharp D, et al. Prostate cancer screening--a physician survey in Missouri. J Community Health. 1998;23: 347-58.
33. Fowler FJ Jr, Bin L, Collins MM, et al. Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. Am J Med. 1998;104:526-32.
34. Austin OJ, Valente S, Hasse LA, Kues JR. Determinants of prostate-specific antigen test use in prostate cancer screening by primary care physicians. Arch Fam Med. 1997;6:453-8.
35. Fawzy A, Fontenot C, Guthrie R, Baudier MM. Practice patterns among primary care physicians in benign prostatic hyperplasia and prostate cancer. Fam Med. 1997;29:321-5.
36. Kripalani S, Weinberg AD, Cooper HP. Screening for breast and prostate cancer: a survey of Texas primary care physicians. Tex Med. 1996;92:59-67.
37. McKnight JT, Tietze PH, Adcock BB, Maxwell AJ, Smith WO, Nagy MC. Screening for prostate cancer: a comparison of urologists and primary care physicians. South Med J. 1996;89:885-8.
38. Hoffman RM, Papenfuss MR, Buller DB, Moon TE. Attitudes and practices of primary care physicians for prostate cancer screening. Am J Prev Med. 1996;12:277-81.
39. Mettlin C, Lee F, Drago J, Murphy GP. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer. 1991;67:2949-58.
40. Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin. 1993;43:42-6.
41. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1993;150(2 Pt 1):379-85.
42. Sandhu DP, Munson KW, Benghiat A, Hopper IP. Natural history and prognosis of prostate carcinoma in adolescents and men under 35 years of age. Br J Urol. 1992;69:525-9.
The authors thank Drs. Michael J. Barry and John H. Wasson and other members of the Prostate Patient Outcomes Research Team for their insights and helpful comments on earlier versions of the manuscript.
Supported in part by a grant from the American Urological Association and the American Federation for Urological Disease.
Dr. Lars Ellison, VA Outcomes Group (111B), Department of Veterans Affairs Medical Center, White River Junction, VT 05009; telephone: 802-296-6369, fax: 802-296-6325; e-mail: firstname.lastname@example.org.
Have questions about the new ABIM MOC Program?
One Click to Confidence - Free to members
ACP Smart Medicine is a new, online clinical decision support tool specifically for internal medicine. Get rapid point-of-care access to evidence-based clinical recommendations and guidelines. Plus, users can easily earn CME credit. Learn more